江苏沃森生物技术

Jiangsu Walvax Biotechnology is a core subsidiary of Walvax Biotechnology Co., Ltd., located in the China Medical City in Taizhou, Jiangsu Province. The company serves as a primary industrialization and manufacturing base for the parent group's advanced vaccine portfolio, including the 13-valent pneumococcal conjugate vaccine (PCV13) and the bivalent human papillomavirus (HPV) vaccine. Jiangsu Walvax operates state-of-the-art facilities designed to meet international GMP standards, enabling the large-scale production of complex biologics. The company is instrumental in Walvax's mission to provide affordable, high-quality vaccines to both the Chinese domestic market and global health initiatives. Through its focus on R&D translation and manufacturing excellence, Jiangsu Walvax has become a significant player in the global vaccine supply chain.